Venmax Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26
Venmax Drugs and Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 9:31 pm
Venmax Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 528 (+300.6% YoY | +113.0% QoQ) ■ EBITDA: 20.1 (+329.7% YoY | +71.1% QoQ) ■ EBITDA Margin (%): 3.8 (+26 bps YoY | -93 bps QoQ) ■ PAT: 12.0 (+393.0% YoY | +3.2% QoQ) ■ EPS (INR): 0.08 (+60.0% YoY | -20.0% QoQ)
Original exchange filing (PDF)
More announcements from Venmax Drugs and Pharmaceuticals Ltd
- Statement of Deviation and Variation for the Quarter ended September 30, 2026. · 12 Nov 2026
- Unaudited Financial Results for the Quarter and Half Year ended September 30, 206. · 12 Nov 2026
- Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Unaudited .... · 12 Nov 2026
- Venmax Drugs and Pharmaceuticals Limited has submitted the Exchange a copy if Scrutinizer report along with voting results of court convened General Meeting held on October 24, 2026. · 27 Oct 2026
- Venmax Drugs and Pharmaceuticals Limited has informed the Bombay Stock Exchange regarding Proceedings of court convened General Meeting held today i.e. October 24, 2026. · 24 Oct 2026
- Voting Results along with the Scrutinizers Report of the 37th Annual General Meeting of the Company held on 26th September 2026 through VC/OAVM. · 28 Sept 2026
- Summary of the proceedings of 37th Annual General Meeting of the shareholders held at 12.30 P.M. through video conferencing mode. · 26 Sept 2026
- Venmax Drugs and Pharmaceuticals Limited has informed exchange about the meeting of equity shareholders of the Company pursuant to the order passed by Hon. NCLT, Hyderabad bench II in respect .... · 23 Sept 2026
